-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine TherapyDaiichi Sankyo2025-03-06 15:57:51ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic
-
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2025-01-31 15:16:20Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated
-
Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevailDaiichi Sankyo2025-01-22 06:59:30Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and
-
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily WithdrawnDaiichi Sankyo2024-12-24 08:26:44Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
-
Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic AcidDaiichi Sankyo2024-11-25 15:22:25Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With
-
Daiichi Sankyo Opens New Affiliate for Oncology in GreeceDaiichi Sankyo2024-07-15 09:32:07Daiichi Sankyo Opens New Affiliate for Oncology in Greece
-
New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groupsDaiichi Sankyo2024-08-06 16:38:16New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse
-
Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in EuropeDaiichi Sankyo2024-08-06 16:38:29Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe
-
First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular riskDaiichi Sankyo2024-08-06 16:38:40First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼,
-
CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular eventsDaiichi Sankyo2024-03-25 09:37:57CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose
